Biote Corp. Announces Leadership Change: Bob Peterson Named Interim CEO
Biote Corp. (NASDAQ: BTMD), a leader in hormone optimization and healthy aging solutions, has announced a significant leadership transition. Effective June 8, 2026, Bob Peterson, who currently serves as both Chief Financial Officer (CFO) and Chief Business Officer, will step into the role of Interim Chief Executive Officer and Director. This comes as Bret Christensen, the outgoing CEO, steps down for family and personal reasons but will remain on the Board of Directors. In addition, Marc Beer, Biote’s Chairman, will assume the role of Executive Chairman.
Key Points in the Announcement
- Leadership Transition: Bret Christensen is stepping down as CEO for family and personal reasons, but will continue serving as a director. Bob Peterson is appointed as Interim CEO, leveraging his extensive experience as CFO and Chief Business Officer. Marc Beer, the current Chairman, will take an expanded role as Executive Chairman.
- Operational Continuity: The company emphasized Peterson’s integral role in financial strategy, operational scaling, and integration of Asteria Health. The Board expressed confidence in Peterson’s ability to provide continuity and clear direction during this transition.
- Company Strategy and Progress: Over the past year, Biote has strengthened its commercial organization, expanded its sales team, and enhanced practitioner support. These initiatives have set a solid foundation for sustainable, long-term profitable growth.
-
2026 Financial Guidance Reaffirmed: Biote reaffirmed its full year 2026 guidance:
- Revenue above \$190 million
- Adjusted EBITDA above \$38 million
- Return to procedure revenue growth in the second half of 2026
- Executive Search Underway: The Board has retained an executive search firm to identify and evaluate CFO candidates, indicating a continued focus on maintaining a strong executive team.
Potential Price-Sensitive Information for Shareholders
- Leadership Change: CEO transitions can impact investor sentiment, especially when the outgoing CEO departs for personal reasons. However, the retention of Bret Christensen on the Board and Bob Peterson’s deep operational experience are intended to minimize disruption.
- Reaffirmation of Guidance: The confirmation of revenue and EBITDA targets for 2026 may reassure shareholders about the company’s ongoing performance and growth trajectory despite the leadership change.
- Operational and Organizational Initiatives: The company’s focus on scalability, cross-functional execution, and long-term growth, along with recent commercial and sales enhancements, may position Biote for improved performance in the coming quarters.
- Risks and Forward-Looking Statements: Biote highlighted risks associated with management transitions, execution of strategic priorities, successful restructuring, dietary supplement market acceptance, and regulatory challenges. These risks should be carefully considered by investors.
Detailed Insights for Investors
Bob Peterson’s appointment as Interim CEO reflects a deliberate effort by the Board to ensure leadership continuity and leverage his deep knowledge of Biote’s operations and strategy. Peterson has overseen critical aspects of Biote’s financial strategy and operational scaling, including the successful integration of Asteria Health. His expanded responsibilities as Chief Business Officer, in addition to CFO, signal the Board’s confidence in his leadership.
Over the past twelve months, Biote has made substantial progress in strengthening its commercial organization, expanding its sales force, and enhancing practitioner support. These strategic initiatives are designed to support sustainable, long-term profitable growth and position the company as a leading provider of evidence-based therapeutic wellness solutions.
The reaffirmation of financial guidance for 2026—revenue above \$190 million, Adjusted EBITDA above \$38 million, and anticipated return to procedure revenue growth in the second half—provides investors with clarity and confidence in the company’s outlook. The ongoing executive search for a new CFO underscores Biote’s commitment to maintaining strong financial leadership.
The company also highlighted a number of forward-looking risks, including management transition risks, successful execution of strategic priorities, market acceptance of new products, regulatory and competitive challenges, and potential impacts from geopolitical tensions and natural disasters. Investors should monitor these factors as they may influence Biote’s performance and share value.
Contact Information
- Investor Relations: Eric Prouty, AdvisIRy Partners ([email protected])
- Media: [email protected]
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties. Investors are encouraged to review official filings and consult their financial advisors before making investment decisions. Biote Corp. assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.
